Considerations for BRAF V600E Mutations in mCRC

News
Video

Related Videos
Video 8 - "Future Outlook for RET Fusion-Targeted Therapies"
Video 7 - "Impact and Positioning of Tumor Agnostic Approvals"
Video 14 - "Toxicity Profiles for DTC Guidelines Therapies"
Video 13 - "Understanding the Impact of COSMIC-311 and Sequencing in DTC"
Núria Agustí Garcia, MD
Related Content
Mark D. Tyson, II, MD, MPH

Cretostimogene Monotherapy Elicits Durable CRs in High-Risk NMIBC

May 3rd 2024
Article
Ryan Merkow, MD, MS, associate professor, surgery, director, Surgical Cancer Quality, associate director, Health Services Research, Department of Surgery, director, Hepatic Artery Infusion Pump Program, University of Chicago Medicine Comprehensive Cancer Center and Cancer Service Line; Louise Catherine Connell, MB BCh BAO, BMedSc, assistant attending physician, Memorial Sloan Kettering Cancer Center

Merkow and Connell Highlight Considerations for HAI Pump Use in CRC

May 2nd 2024
Podcast
Stenoparib in Ovarian Cancer | Image Credit: © magicmine - stock.adobe.com

Phase 2 Trial Closure Clears a Path for Accelerated Development of Stenoparib in Ovarian Cancer

May 3rd 2024
Article
Amin Nassar, MD, hematology/oncology fellow, Yale University; Elias Bou Farhat, MD, postdoctoral research fellow, Department of Medicine, Brigham and Women’s Hospital

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

April 29th 2024
Podcast
Rebecca Klisovic, MD, of University Hospitals Seidman Cancer Center

Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection

May 3rd 2024
Article
Leland Metheny, MD, Case Western Reserve University

Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma

May 2nd 2024
Article